New drug duo aims to tackle tough leukemia
NCT ID NCT06382168
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a combination of two drugs, DFP-10917 and venetoclax, in 39 adults with acute myeloid leukemia that has relapsed or not responded to prior treatments. DFP-10917 is given as a continuous 14-day IV infusion, while venetoclax is taken orally for 10-14 days each cycle. The goal is to find a safe dose and see if the combination can help control the leukemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DFP-10917 and venetoclax
What this could lead to
If successful, this combination could offer a new treatment option for people with acute myeloid leukemia that has come back or not responded to prior therapy.
What could go wrong
This is an early-phase trial with only 39 participants, so results may not apply broadly. The drugs may cause serious side effects, and the combination might not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27157, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCI Chao Family Comprehensive Cancer Center
RECRUITINGOrange, California, 92868, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Vermont Cancer Center
RECRUITINGBurlington, Vermont, 05401, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Virginia Cancer Center
RECRUITINGCharlottesville, Virginia, 22911, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••